• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

MAO-B 和 COMT 抑制剂：对大脑多巴胺水平的影响及其在帕金森病中的应用。

Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.

机构信息

Neuroscience Group, Rappaport Faculty of Medicine, Haifa, Israel.

出版信息

J Neural Transm (Vienna). 2019 Apr;126(4):433-448. doi: 10.1007/s00702-018-1952-7. Epub 2018 Nov 1.

DOI:10.1007/s00702-018-1952-7
PMID:30386930
Abstract

MAO-B and COMT are both enzymes involved in dopamine breakdown and metabolism. Inhibitors of these enzymes are used in the treatment of Parkinson's disease. This review article describes the scientific background to the localization and function of the enzymes, the physiological changes resulting from their inhibition, and the basic and clinical pharmacology of the various inhibitors and their role in treatment of Parkinson's disease.

摘要

MAO-B 和 COMT 都是参与多巴胺分解和代谢的酶。这些酶的抑制剂被用于治疗帕金森病。本文综述了这些酶的定位和功能的科学背景、其抑制所导致的生理变化，以及各种抑制剂的基础和临床药理学及其在帕金森病治疗中的作用。

相似文献

1
Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.MAO-B 和 COMT 抑制剂：对大脑多巴胺水平的影响及其在帕金森病中的应用。
J Neural Transm (Vienna). 2019 Apr;126(4):433-448. doi: 10.1007/s00702-018-1952-7. Epub 2018 Nov 1.
2
Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase.查尔酮的硝基邻苯二酚衍生物作为单胺氧化酶和儿茶酚-O-甲基转移酶的抑制剂
Cent Nerv Syst Agents Med Chem. 2018;18(2):115-127. doi: 10.2174/1871524918666180426125714.
3
Evaluation of Selected Natural Compounds as Dual Inhibitors of Catechol-O-Methyltransferase and Monoamine Oxidase.选定天然化合物作为儿茶酚-O-甲基转移酶和单胺氧化酶双重抑制剂的评估
Cent Nerv Syst Agents Med Chem. 2019;19(2):133-145. doi: 10.2174/1871524919666190619090852.
4
Evaluation of nitrocatechol chalcone and pyrazoline derivatives as inhibitors of catechol-O-methyltransferase and monoamine oxidase.评价硝基邻苯二酚查尔酮和吡唑啉衍生物作为儿茶酚-O-甲基转移酶和单胺氧化酶抑制剂的作用。
Bioorg Med Chem Lett. 2020 Jun 15;30(12):127188. doi: 10.1016/j.bmcl.2020.127188. Epub 2020 Apr 11.
5
Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition.灵长类动物大脑中多巴胺代谢与神经传递与单胺氧化酶A和B抑制的关系
J Neural Transm Gen Sect. 1993;91(2-3):181-95. doi: 10.1007/BF01245231.
6
The inhibition of catechol O-methyltransferase and monoamine oxidase by tetralone and indanone derivatives substituted with the nitrocatechol moiety.含硝基儿茶酚部分取代的四氢萘酮和茚满酮衍生物对儿茶酚-O-甲基转移酶和单胺氧化酶的抑制作用。
Bioorg Chem. 2021 Sep;114:105130. doi: 10.1016/j.bioorg.2021.105130. Epub 2021 Jun 28.
7
Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations.帕金森病中单胺氧化酶-B 和儿茶酚-O-甲基转移酶抑制的临床获益：实际考虑因素。
J Neural Transm (Vienna). 2023 Jun;130(6):847-861. doi: 10.1007/s00702-023-02623-8. Epub 2023 Mar 24.
8
MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.MAO-B 和 COMT 基因变异与帕金森病患者左旋多巴治疗反应的相关性。
J Clin Pharmacol. 2018 Jul;58(7):920-926. doi: 10.1002/jcph.1096. Epub 2018 Mar 26.
9
Identification and optimization of nitrophenolic analogues as dopamine metabolic enzyme inhibitors for the treatment of Parkinson's disease.鉴定和优化作为多巴胺代谢酶抑制剂的硝基酚类似物，用于治疗帕金森病。
Bioorg Chem. 2024 Jul;148:107488. doi: 10.1016/j.bioorg.2024.107488. Epub 2024 May 23.
10
The role of monoamine oxidase and catechol O-methyltransferase in dopaminergic neurotransmission.单胺氧化酶和儿茶酚-O-甲基转移酶在多巴胺能神经传递中的作用。
J Neural Transm Suppl. 1995;45:35-45.

引用本文的文献

1
Enzyme inhibitory activity of marine alkaloid aaptamines for neurodegenerative diseases: an study.海洋生物碱aaptamines对神经退行性疾病的酶抑制活性：一项研究。
R Soc Open Sci. 2025 Jul 16;12(7):250697. doi: 10.1098/rsos.250697. eCollection 2025 Jul.
2
Biogenic Amine Metabolism and Its Genetic Variations in Autism Spectrum Disorder: A Comprehensive Overview.自闭症谱系障碍中的生物胺代谢及其基因变异：全面概述
Biomolecules. 2025 Apr 7;15(4):539. doi: 10.3390/biom15040539.
3
The Role of MAO-B Inhibitors in Fatigue in Parkinson's Disease: A Narrative Review.

本文引用的文献

1
Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease.恩他卡朋增效治疗与转换治疗对帕金森病运动波动患者的疗效。
Neurology. 2018 May 22;90(21):e1849-e1857. doi: 10.1212/WNL.0000000000005557. Epub 2018 Apr 25.
2
Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations.帕金森病的疾病修饰：当前方法、挑战和未来考虑。
Mov Disord. 2018 May;33(5):660-677. doi: 10.1002/mds.27360. Epub 2018 Apr 11.
3
90 years of monoamine oxidase: some progress and some confusion.
单胺氧化酶B抑制剂在帕金森病疲劳中的作用：一项叙述性综述
J Clin Med. 2025 Apr 10;14(8):2598. doi: 10.3390/jcm14082598.
4
Anti-Stress Effects of Berk. Enzymatic Extracts: A Preclinical Study.伯克氏酶提取物的抗应激作用：一项临床前研究。
Nutrients. 2025 Mar 6;17(5):914. doi: 10.3390/nu17050914.
5
Recent advances in nanotechnology for Parkinson's disease: diagnosis, treatment, and future perspectives.帕金森病纳米技术的最新进展：诊断、治疗及未来展望。
Front Med (Lausanne). 2025 Jan 22;12:1535682. doi: 10.3389/fmed.2025.1535682. eCollection 2025.
6
Exceeding the Limits with Nutraceuticals: Looking Towards Parkinson's Disease and Frailty.营养保健品突破极限：展望帕金森病与身体虚弱问题
Int J Mol Sci. 2024 Dec 26;26(1):122. doi: 10.3390/ijms26010122.
7
The Combined Use of Levodopa/Benserazide and Pramipexole Proves Beneficial for Managing Parkinson's Disease.左旋多巴/苄丝肼与普拉克索联合使用对帕金森病的治疗有益。
Actas Esp Psiquiatr. 2024 Dec;52(6):769-776. doi: 10.62641/aep.v52i6.1711.
8
A Comprehensive Review on Repurposing the Nanocarriers for the Treatment of Parkinson's Disease: An Updated Patent and Clinical Trials.纳米载体用于治疗帕金森病的再利用综合综述：最新专利与临床试验
CNS Neurol Disord Drug Targets. 2025;24(3):181-195. doi: 10.2174/0118715273323074241001071645.
9
A Comprehensive Approach to Parkinson's Disease: Addressing Its Molecular, Clinical, and Therapeutic Aspects.帕金森病的综合治疗方法：探讨其分子、临床和治疗方面。
Int J Mol Sci. 2024 Jun 29;25(13):7183. doi: 10.3390/ijms25137183.
10
Drug Development for Alzheimer's and Parkinson's Disease: Where Do We Go Now?阿尔茨海默病和帕金森病的药物研发：我们如今何去何从？
Pharmaceutics. 2024 May 24;16(6):708. doi: 10.3390/pharmaceutics16060708.
90 年的单胺氧化酶：一些进展和一些困惑。
J Neural Transm (Vienna). 2018 Nov;125(11):1519-1551. doi: 10.1007/s00702-018-1881-5. Epub 2018 Apr 10.
4
Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review.在帕金森病患者的药物治疗中加入儿茶酚-O-甲基转移酶抑制剂是否有益？系统评价。
J Parkinsons Dis. 2018;8(2):217-231. doi: 10.3233/JPD-171225.
5
International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.国际帕金森病和运动障碍学会循证医学综述：帕金森病运动症状治疗的最新进展。
Mov Disord. 2018 Aug;33(8):1248-1266. doi: 10.1002/mds.27372. Epub 2018 Mar 23.
6
Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects.单胺氧化酶-B 抑制剂治疗帕金森病：临床药理学方面。
J Neural Transm (Vienna). 2018 Nov;125(11):1751-1757. doi: 10.1007/s00702-018-1876-2. Epub 2018 Mar 22.
7
Synergistic neuroprotective effect of rasagiline and idebenone against retinal ischemia-reperfusion injury via the Lin28-let-7-Dicer pathway.雷沙吉兰和艾地苯醌通过Lin28-let-7-Dicer途径对视网膜缺血再灌注损伤的协同神经保护作用。
Oncotarget. 2018 Jan 30;9(15):12137-12153. doi: 10.18632/oncotarget.24343. eCollection 2018 Feb 23.
8
Monoamine Oxidases.单胺氧化酶
Subcell Biochem. 2018;87:117-139. doi: 10.1007/978-981-10-7757-9_5.
9
Catechol-O-methyltransferase (COMT) genetic variants are associated with cognitive decline in patients with Parkinson's disease.儿茶酚-O-甲基转移酶（COMT）基因变异与帕金森病患者的认知能力下降有关。
Parkinsonism Relat Disord. 2018 May;50:48-53. doi: 10.1016/j.parkreldis.2018.02.015. Epub 2018 Feb 9.
10
Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.不可逆 MAO-B 抑制剂司来吉兰和雷沙吉兰在帕金森病中的神经保护作用的药理学方面。
J Neural Transm (Vienna). 2018 Nov;125(11):1735-1749. doi: 10.1007/s00702-018-1853-9. Epub 2018 Feb 7.